Exchange: NASDAQ·Updated 07:30 PM EDT
ACRV logo

ACRV ACRIVON THERAPEUTICS INC

$1.88
$0.04
(2.14%)
Today
Closed $1.91
$0.0267
(1.40%)
After Hours
Reported EarningsAug 12
Mkt Cap$80.14M
Vol192,042.00

About ACRV

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
41

Bearish Sentiment

How do you feel about ACRV?

bosch49
$ACRV Phase 2b results could be coming during the mid November Q3 ER. Very exciting. IMHO we should currently be $300 Million market cap, billions upon great results. Great opportunity here imho.
7
bosch49
$ACRV News very likely to be positive. This company presents a 1000% near term opportunity imho. Could be more if Eli Lily buys right after news. Big months coming up! $BCTX $NLY $KSS
7
bosch49
$ACRV Copy and Pasted from Yahoo finance (part 1) All that follows is just my opinion.... Agree that the current market cap appears quite low considering the potential. Per the CEO on the Cantor Global discussion, the market for the ACR-368 would be based on about 18,000 patients per year at 7 months treatment and $30,000/month drug cost resulting by my calculation in >$3B revenue per year and I gotta think that's at a huge gross margin, even sales at a percentage of this potential would be massive for this company versus its current capitalization. If the interim data in November is stellar, especially wrt Arm 4, then they can push for the breakthrough designation and rapid acceleration towards drug approval. That all said, this company needs more financing, so it remains to be seen if that means dilution (most likely) and how that impacts the value. In the near term, indications per CEO are that there may be some announcement in regard to the AP3 platform and potential partnerships
2
Bullbarbise
$ACRV Ceo, has just to do one thing. Buy stocks and show to market that is the first doing this and trusting in what he is doing. It is a shame that ACRV it is not able to mantein 2 dollars value. More than a shame for a stock where analysts are having from 8 to 19 dollars target prices. Cases are 2: 1) Analysts are all people that it is better they go to fish. 2) This is pure speculation and stock holders are thinking to play just betweekn 1.4 to 2.19. And this is the most sad scenario.
1
Bullbarbise
$ACRV VOLUMES = ZERO. With no news or communications it will stay stocked. But the day will come news is day by day close and someone will start to keep position.......
Bullbarbise
$ACRV I'm bullish, but, starting to be tired of this stock. Market cap less than liquidity is a pure joke. Especially under near future catalyst. We will see. For the moment I'll keep this occasion to accumulate more.

Advertisement|Remove ads.